Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

ClinicalTrials.gov ID: NCT00404612

Public ClinicalTrials.gov record NCT00404612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis

Study identification

NCT ID
NCT00404612
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lux Biosciences, Inc.
Industry
Enrollment
218 participants

Conditions and interventions

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2007 (Type not available)
Primary completion
Nov 2008 (Actual)
Completion
May 2009 (Actual)
Last update posted
Oct 11, 2012

2007 – 2009

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233 —
Retinal Consultants of Arizona Phoenix Arizona 85014 —
University of Illinois - Chicago Chicago Illinois 60612 —
Midwest Eye Institute Indianapolis Indiana 46280 —
Wilmer Eye Institute Baltimore Maryland 21287 —
Massachusetts Eye and Ear Infirmary Boston Massachusetts 02114 —
Massachusetts Eye Research and Surgery Institute Cambridge Massachusetts 02142 —
Associated Retinal Consultants, PC Grand Rapids Michigan 49546 —
Tauber Eye Center Kansas City Missouri 64111 —
UMDNJ-New Jersey Medical School, Ophthalmology Dept. Newark New Jersey 07103 —
New York Eye & Ear Hospital New York New York 10003 —
Duke University Eye Center, Erwin Road Durham North Carolina — —
Oregon Health Sciences University Portland Oregon 97201 —
Texas Retina Associates Arlington Texas 76012 —
Retina Research Center Austin Texas 78705 —
Texas Retina Associates Dallas Texas 75231 —
Vitreoretinal Consultants Houston Texas 77030 —
Retina & Uveitis Consultants of Texas San Antonio Texas 78240 —
Viginia Eye Consultants Norfolk Virginia 23502 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00404612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 11, 2012 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00404612 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →